Adding daratumumab and hyaluronidase-fihj to lenalidomide, bortezomib and dexamethasone reduced the risk of progression. Selinexor is an oral inhibitor for the treatment of relapsed or refractory multiple myeloma. Dr. Pui, of St. Jude Children’s Research Hospital, discusses his lifelong commitment to being a pediatric oncologist. CanScan uses low-depth whole-genome sequencing to detect early cancer signals with 99% specificity. In a clinical trial, relma-cel demonstrated a three-month ORR of 81.36% in patients with relapsed or refractory MCL. Researchers are working to define and validate the ways in which mass spectrometry can aid in MM diagnosis and monitoring. This manufacturing process change results in a shorter manufacturing time for axi-cel from 16 days to 14 days. Gilead said that it "will not pursue further development of magrolimab in hematologic cancers." The novel GPRC5D-targeted CAR T-cell therapy first gained approval by China’s NMPA following results from the POLARIS ... ZUMA-7 showed that axi-cel significantly improved OS compared with standard of care in relapsed or refractory LBCL. Hematologist-oncologists are increasingly turning to podcasts and social media to learn about new data and to share research. Thomas Martin, MD, reflects on what's in store for 2024—including the SOHO Annual Meeting, myeloma advancements, and more. Researchers from St. Jude Children’s Research Hospital developed SJ3149, a selective and potent degrader of CK1α protein. Cancer Research & Treatment Fund (CR&T) invests in research related to the prevention and treatment of blood cancers. The past two decades have witnessed a rapid change in the treatment of acute lymphoblastic leukemia. Mariia Mikhaleva MD, a research fellow at the Dana-Farber Cancer Institute, describes how it felt to receive the award. The CHMP of the European Medicines Agency gave a positive recommendation for the Marketing Authorization approval of ide-cel. Patients' coping strategies prior to HSCT had significant effects on their psychological distress and quality of life. The agency's statement follows potential risks identified by the FDA Adverse Event Reporting System. The study aimed to describe the myeloma-defining events and clinical presentations leading to multiple myeloma diagnosis.